Ripple Therapeutics Analysis: $79M Raised
What is Ripple Therapeutics?
Ripple Therapeutics develops ophthalmic therapeutics using a proprietary prodrug technology that enables sustained drug delivery without polymers. Their lead product, IBE-814 IVT, is a biodegradable intravitreal dexamethasone prodrug implant targeting diabetic macular edema and other indications. The company focuses on improving patient outcomes and reducing treatment burdens through innovative drug delivery solutions.
Location
101 College St, Toronto, Ontario M5G 1L7, Canada
Employees
11-50
Founded
2019
Funding Status
Series C
Product Features & Capabilities
- IBE-814 IVT intravitreal dexamethasone prodrug implant
- RTC-620 biodegradable intracameral implant for glaucoma
- Prodrug technology for sustained drug delivery
Use Cases
Treat diabetic macular edema with IBE-814 IVT implant; Manage retinal vein occlusion using sustained release implants; Develop glaucoma therapies with RTC-620 implant; Conduct preclinical studies for dry AMD/GA; Collaborate with AbbVie for glaucoma management solutions
Other Considerations
Raised $10M in seed capital; Secured $15M Series A financing; Partnered with AbbVie for glaucoma therapy development; Collaborated with Glaukos for sustained release implants
See something that needs updating? Suggest edits to this profile.